(PO23-07-22) Wild-Blueberry Volatile and Phenolic Fractions Mitigate LPS-Induced Inflammatory Responses in Whole Blood of Children

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

LF

Laura Felgus-Lavefve, PhD Student
– Graduate Research Assistant, University of Arkansas, San Jose, California, United States

Co-Author(s)

SA

Sean H. Adams
– University of California, Davis
LH

Luke Howard, Ph.D.
– Professor, University of Arkansas, Fayetteville, Arkansas, United States
KO

Kikumi D. On-Moore
– Senior Research Associate, Arkansas Children's Nutrition Center, Little Rock, Arkansas, United States
YK

Yihong Kaufmann, Ph.D
– UAMS, Department of Otolaryngology-Head and Neck Surgery, Little Rock, Arkansas, United States
ED

Eva C. Diaz, MD
– Assistant Professor , Arkansas Children's Nutrition Center, LITTLE ROCK, Arkansas, United States

Disclosure(s):

Laura Felgus-Lavefve, PhD Student: No relevant financial relationship(s) with ineligible companies to disclose.

Objectives: The anti-inflammatory effects of berries have been attributed to their polyphenol content. In vitro models of activated murine macrophages have shown that volatiles in berries exert anti-inflammatory effects as well. However, human data in this area are scarce. To address this limitation we measured the effects of wild-blueberry phenolic (WBB-P) and WBB volatile (WBB-V) fractions in LPS-treated whole blood (WB) of children.

Methods: Fasting WB was collected (n=19), and treated with high and low doses of either WBB-P (2 μg/mL or 0.02 μg/mL), WBB-V (2 ng/mL or 0.02 ng/mL), or culture medium (RPMI) as control and incubated for 1 hour at 37°C. To evaluate potential anti-inflammatory effects of WBB molecules, lipopolysaccharide (LPS, 0.2 μg/mL or 1 μg/mL) was added to the wells, and samples incubated for 48 hours. Interleukin (IL)-1β, IL-6, IL-10 and TNF-α supernatant concentrations were measured using enzyme-linked immunosorbent assay. One-factor ANOVA analysis with participant ID as random effect was used to compare cytokine concentrations (ng/ml) of WBB fraction treatments against their respective RPMI + LPS controls.

Results: Children (12.0±0.6 years old) were predominantly white (79%), and with a BMI percentile of 51±35. At both LPS levels, IL-6 concentrations were lower in the high-dose WBB-P and WBB-V treatments compared to the control group. LPS-High: WBB-P: 22.2±6.7 vs. RPMI: 28.2±8.3 (p=0.005); WBB-V: 24.4±7.2 vs. RPMI: 28.2±8.3 (p=0.013). LPS-low: WBB-P: 20.4±5.5 vs. RPMI: 26.6±7.7 (p=0.001); WBB-V: 20.6±6.5 vs. RPMI: 26.6±7.7 (p < 0.0001). At the lowest LPS level, TNF-α concentration was 23% lower in the high-dose WBB-V treatment compared to the control group (WBB-V: 0.45±0.06 vs. RPMI: 0.55±0.12, p=0.003). IL-1β, and IL-10 were not modified by WBB fraction treatments.

Conclusions: These preliminary results indicate that both WBB-P and WBB-V fractions mitigate inflammatory responses in LPS treated WB of children. Blueberry fractions do not impact IL-1β or IL-10 secretion by immune cells in WB.

Funding Sources: Center for Childhood Obesity Prevention NIH-NIGMS 5P20GM109096. USDA-ARS 6026-51000-012-06S. The Arkansas Center for Advancing Pediatric Therapeutics NIH 8UG1OD024945.